SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| BOURLA ALBERT | Chairman & CEO, Director | 2026-08-12 | Open-market buy | 38000 | $1.0M |
| BLAYLOCK RONALD E | Director | 2026-08-05 | Open-market buy | 39231 | $999K |
| Buckley Mortimer J | Director | 2026-08-05 | Open-market buy | 37632 | $960K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-08-05 | Open-market sell | 3278 | $83K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-06-09 | Open-market sell | 2000 | $51K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-03-04 | Tax withholding | 826 | $22K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-03-03 | Grant/award | 16311 | $0 |
| DAMICO JENNIFER B. | SVP & Controller | 2026-03-03 | Grant/award | 5408 | $0 |
| DAMICO JENNIFER B. | SVP & Controller | 2026-02-27 | Tax withholding | 655 | $18K |
| McDermott Michael | Executive Vice President | 2026-02-26 | Tax withholding | 3503 | $95K |
| BOSHOFF CHRISTOFFEL | President, R&D | 2026-02-25 | Grant/award | 13383 | $0 |
| BOSHOFF CHRISTOFFEL | President, R&D | 2026-02-25 | Tax withholding | 6833 | $185K |
| BOURLA ALBERT | Chairman & CEO, Director | 2026-02-25 | Option exercise | 491626 | $16.6M |
| BOURLA ALBERT | Chairman & CEO, Director | 2026-02-25 | Tax withholding | 8303 | $225K |
| BOURLA ALBERT | Chairman & CEO, Director | 2026-02-25 | Tax withholding | 467241 | $12.6M |
| DAMICO JENNIFER B. | SVP & Controller | 2026-02-25 | Option exercise | 17558 | $594K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-02-25 | Tax withholding | 361 | $10K |
| DAMICO JENNIFER B. | SVP & Controller | 2026-02-25 | Tax withholding | 16687 | $449K |
| Fonseca Lidia | Executive Vice President | 2026-02-25 | Option exercise | 56888 | $1.9M |
| Fonseca Lidia | Executive Vice President | 2026-02-25 | Tax withholding | 1058 | $29K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regulatory and reimbursement risk has escalated sharply and broadly, driven by the OBBBA's Medicaid/Medicare cuts, MFN drug pricing agreements, expanded EU regulatory mandates, and FDA/CDC operational disruptions — spanning pricing, access, approval timelines, and market coverage simultaneously. Competitive pressure compounds the picture via new tariff obligations, managed care access barriers, accelerated patent cliff language, and emerging China competition. The breadth of worsening across five or more distinct themes — regulatory compliance, pricing, market access, technology, and competitive dynamics — meets the major threshold.
2 company-specific · 5 common-mode
EMA negative opinion on Oxbryta benefit-risk and suspension recommendation escalates regulatory risk. Ongoing FDA engagement signals unresolved U.S. approval status.
POST-AUTHORIZATION/APPROVAL DATA As a condition to granting marketing authorization or approval of a product, the FDA may require, or the sponsor may voluntarily agree to undertake, post-marketing…
Multiple substantive escalations: new Trump tariff agreement with investment obligations and grace-period risks; new managed care access barriers (co-pay disallowance, patient assistance restrictions); accelerated patent cliff language; new competitive threats from China; Seagen/Metsera concentration risk.
RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS: MANAGED CARE TRENDS Private payors, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the…
New major healthcare reform (OBBBA) with significant Medicaid/Medicare cuts, 10M uninsured increase, CDC vaccine recommendation reductions, and specific new regulatory threats (CMMI pilots, MFN initiatives, FDA disclosure policy) materially escalate regulatory and reimbursement risks.
U.S. HEALTHCARE REGULATION The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. Major U.S. healthcare reform occurred with the passage of the OBBBA on…
New material pricing risks: MFN Agreement with Trump Administration, CMMI pilots, ACA subsidy cuts, and additional drug selections (Xeljanz) for price controls. Escalated regulatory pressure.
RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS: PRICING AND REIMBURSEMENT Our future results could be adversely affected by new or changes in U.S. and international governmental…
New disclosure of FDA workforce reductions causing inconsistencies in regulatory evaluations, and CDC's January 2026 unilateral reduction in childhood immunization recommendations—both material regulatory risks.
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. The outcome is…
Substantially expanded AI risk disclosure: new regulatory uncertainty, deployment risks, third-party vendor concentration, and operational impact risks (payor denial automation). Material escalation of emerging technology risk.
INFORMATION TECHNOLOGY AND CYBERSECURITY Significant disruptions of IT systems or breaches of information security could adversely affect our business. We extensively rely upon sophisticated IT…
Added specific EU regulatory risks (Pharma Package, HTA-R, Critical Medicines Act, Biotech Act, AI Act, Data Act, Health Data Space Regulation) and government cost-cutting impacts on regulatory review timelines. Expanded tariff language to include cash flow and liquidity impacts.
CHANGES IN LAWS AND ACCOUNTING STANDARDS Our future results could be adversely affected by changes in laws, regulations or policies, or their interpretation, including, among others, new or changes…
This is a clear earnings release disclosing Pfizer's second-quarter 2026 financial results, including revenues of $15.0 billion, reported loss per share of $(0.04), and adjusted diluted EPS of $0.77. The filing includes updated full-year 2026 revenue guidance raised by $500 million at the midpoint, along with detailed operational performance metrics and product-level revenue drivers. The press release is furnished as Exhibit 99 and constitutes the primary disclosure under Item 2.02.
View raw filing on EDGAR →Dave Denton, Chief Financial Officer, is stepping down from his position effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry. While the filing also discloses the interim appointment of Cecile Guegan as Interim CFO, the principal disclosed action centers on Denton's departure—a material executive departure at the C-suite level. The CFO role is critical to investor assessment of financial stewardship and strategy execution.
View raw filing on EDGAR →